Correction: Impact of modified risk tobacco product claims on beliefs of US adults and adolescents

El-Toukhy S, Baig SA, Jeong M, et al. Impact of modified risk tobacco product claims on beliefs of US adults and adolescents. *Tobacco Control* 2018;27:s62-s69. doi:tobaccocontrol-2018-054315

The correct version of table 3 is as follows:

Table 3 Path coefficients from mediation analysis for the effects of lower risk and lower exposure claims on susceptibility to use MRTPs

	Perceived quantity				Mediated effect	Perceived risk				Mediated effect
	a	b	c	c'		a	b	c	c'	
Experiment 1										
Adults (n=2352)										
Risk claim	-0.17**	-0.41**	0.12*	0.05	0.07**	-0.14**	-0.34**	0.12**	0.08*	0.05**
IQOS vs snus	-0.28**	-0.40**	0.30**	0.19**	0.11**	-0.21**	-0.33**	0.30**	0.23**	0.07**
E-cig vs snus	-0.40**	-0.40**	0.30**	0.14**	0.16**	-0.29**	-0.33**	0.30**	0.20**	0.09**
Adolescents (n=480)										
Risk claim	-0.28**	-0.17**	0.02	-0.02	0.05**	-0.23*	-0.20**	0.02	-0.02	0.05*
IQOS vs snus	-0.21*	-0.17**	0.01	-0.02	0.04**	-0.18*	-0.20**	0.01	-0.02	0.04*
E-cig vs snus	-0.33**	-0.17**	0.03	-0.03	0.06**	-0.35**	-0.20**	0.03	-0.04	0.07**
Experiment 2										
Adults (n=2445)										
Exposure claim	-0.31**	-0.29**	0.06	-0.03	0.09**	-0.18**	-0.31**	0.06	0.01	0.06**
IQOS vs snus	-0.12*	-0.27**	0.31**	0.27**	0.03**	-0.12*	-0.30**	0.31**	0.27**	0.04*
E-cig vs snus	-0.15**	-0.27**	0.27**	0.23**	0.04**	-0.17**	-0.30**	0.27**	0.22**	0.05**
Adolescents (n=489)										
Exposure claim	-0.39**	-0.19**	0.01	-0.07	0.07**	-0.19*	-0.18**	0.01	-0.03	0.04*
IQOS vs snus	-0.21*	-0.17**	0.05	0.01	0.04*	-0.21*	-0.18**	0.05	0.01	0.04*
E-cig vs snus	-0.20*	-0.17**	0.08	0.05	0.03*	-0.21*	-0.18**	0.08	0.04	0.04*

a, path from independent variable to mediator. b, path from mediator to dependent variable. c, path from independent variable to dependent variable (total effect). c' c path adjusted for mediator (direct effect).

*p < .05, **p < 0.001.

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Tob Control 2020;29:360. doi:10.1136/tobaccocontrol-2018-054315corr1